These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18210304)

  • 1. Radiological assessment of tumour response to anti-cancer drugs: time to reappraise.
    Nygren P; Blomqvist L; Bergh J; Aström G
    Acta Oncol; 2008; 47(2):316-8. PubMed ID: 18210304
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cytostatic therapy of malignant tumors from radiological point of view].
    Quäck J
    Med Welt; 1973 Nov; 24(47):1845-8. PubMed ID: 4775545
    [No Abstract]   [Full Text] [Related]  

  • 3. Thallium-201 imaging in the assessment of tumor response to anti-tumor treatments.
    Berk F; Demir H; Aktolun C
    Q J Nucl Med; 2003 Mar; 47(1):63-74. PubMed ID: 12714957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAMA Oncology Patient Page. The Evolution of a Cancer.
    West HJ; Jin JO
    JAMA Oncol; 2015 Sep; 1(6):850. PubMed ID: 26247697
    [No Abstract]   [Full Text] [Related]  

  • 5. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
    Heinemann V; Stintzing S; Modest DP; Giessen-Jung C; Michl M; Mansmann UR
    Eur J Cancer; 2015 Sep; 51(14):1927-36. PubMed ID: 26188850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanism of and dosage in the combination of ionizing radiation and substances in tumor therapy].
    Streffer C
    Strahlentherapie Sonderb; 1978; 75():1-11. PubMed ID: 555043
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Surgery after. . .].
    Évrard S
    Bull Cancer; 2011 Jan; 98(1):8-9. PubMed ID: 21591297
    [No Abstract]   [Full Text] [Related]  

  • 9. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists.
    Padhani AR; Ollivier L
    Br J Radiol; 2001 Nov; 74(887):983-6. PubMed ID: 11709461
    [No Abstract]   [Full Text] [Related]  

  • 10. NMR-based metabolomics: translational application and treatment of cancer.
    Serkova NJ; Spratlin JL; Eckhardt SG
    Curr Opin Mol Ther; 2007 Dec; 9(6):572-85. PubMed ID: 18041668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiological monitoring of the treatment of solid tumors in practice.
    Ganten MK; Ganten TM; Schlemmer HP
    Rofo; 2014 May; 186(5):466-73. PubMed ID: 24563412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A note on improved statistical approaches to account for pseudoprogression.
    Abrouk N; Oronsky B; Caroen S; Ning S; Knox S; Peehl D
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):621-626. PubMed ID: 29404682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of PET for monitoring cancer therapy and for predicting outcome.
    Weber WA
    J Nucl Med; 2005 Jun; 46(6):983-95. PubMed ID: 15937310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the value of confirming responses in clinical trials in oncology.
    Perez-Gracia JL; Muñoz M; Williams G; Wu J; Carrasco E; Garcia-Ribas I; Peiro A; Lopez-Picazo JM; Gurpide A; Chopitea A; Martín-Algarra S; García-Foncillas J; Blatter J
    Eur J Cancer; 2005 Jul; 41(11):1528-32. PubMed ID: 16026690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary: IMRT for head and neck cancer: many chapters left to write.
    Allen AM; Tishler RB
    Oncologist; 2007 May; 12(5):565-8. PubMed ID: 17522244
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cancerology].
    Rev Med Brux; 1984 Mar; 5(3):171-8. PubMed ID: 6371983
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hyperthermia in oncology--a need for centers with competence and standards].
    Issels R; Hiddemann W
    Dtsch Med Wochenschr; 2003 Sep; 128(39):1997. PubMed ID: 14508693
    [No Abstract]   [Full Text] [Related]  

  • 18. 99mTc sestamibi and 99mTc tetrofosmin scintigraphy for predicting resistance to chemotherapy: a critical review of clinical data.
    Van de Wiele C; Rottey S; Goethals I; Buscombe J; Van Belle S; De Vos F; Dierckx RA
    Nucl Med Commun; 2003 Sep; 24(9):945-50. PubMed ID: 12960592
    [No Abstract]   [Full Text] [Related]  

  • 19. Learning from exceptional drug responders.
    Mullard A
    Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of cancer drugs on survival: often poorly evaluated.
    Prescrire Int; 2009 Aug; 18(102):180-3. PubMed ID: 19746577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.